EIF2AK3 and ovarian carcinoma: Specifically, almost 75% of MM patients (19 out of 25) expressed high levels of PERK, and 30% (7 out of 25) expressed almost 20–80 fold higher PERK compared to the ES2 ovarian cancer cell line that was used as control (Figure 1B).